DENTSPLY SIRONA INC (XRAY) Stock Fundamental Analysis
USA - NASDAQ:XRAY - US24906P1093 - Common Stock
13.16 USD
-0.26 (-1.94%)
13.13 USD
-0.03 (-0.23%)
Taking everything into account, XRAY scores 4 out of 10 in our fundamental rating. XRAY was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While XRAY is still in line with the averages on profitability rating, there are concerns on its financial health. XRAY is cheap, but on the other hand it scores bad on growth. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
XRAY had positive earnings in the past year.
In the past year XRAY had a positive cash flow from operations.
XRAY had negative earnings in 4 of the past 5 years.
In the past 5 years XRAY always reported a positive cash flow from operatings.
1.2 Ratios
XRAY has a Return On Assets (-15.64%) which is comparable to the rest of the industry.
With a Return On Equity value of -48.42%, XRAY perfoms like the industry average, outperforming 50.79% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.66%, XRAY is in the better half of the industry, outperforming 75.92% of the companies in the same industry.
XRAY had an Average Return On Invested Capital over the past 3 years of 4.11%. This is below the industry average of 8.46%.
The last Return On Invested Capital (4.66%) for XRAY is above the 3 year average (4.11%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.64% | ||
| ROE | -48.42% | ||
| ROIC | 4.66% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
XRAY's Operating Margin of 7.87% is fine compared to the rest of the industry. XRAY outperforms 76.44% of its industry peers.
XRAY's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 51.92%, XRAY is in line with its industry, outperforming 44.50% of the companies in the same industry.
XRAY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.87% | ||
| PM (TTM) | N/A | ||
| GM | 51.92% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
XRAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, XRAY has less shares outstanding
Compared to 5 years ago, XRAY has less shares outstanding
XRAY has a worse debt/assets ratio than last year.
2.2 Solvency
XRAY has an Altman-Z score of 1.09. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.09, XRAY is in line with its industry, outperforming 53.93% of the companies in the same industry.
XRAY has a debt to FCF ratio of 17.41. This is a negative value and a sign of low solvency as XRAY would need 17.41 years to pay back of all of its debts.
XRAY's Debt to FCF ratio of 17.41 is fine compared to the rest of the industry. XRAY outperforms 71.73% of its industry peers.
A Debt/Equity ratio of 1.13 is on the high side and indicates that XRAY has dependencies on debt financing.
XRAY has a worse Debt to Equity ratio (1.13) than 79.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.13 | ||
| Debt/FCF | 17.41 | ||
| Altman-Z | 1.09 |
ROIC/WACC0.73
WACC6.36%
2.3 Liquidity
XRAY has a Current Ratio of 1.69. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.69, XRAY is doing worse than 70.68% of the companies in the same industry.
A Quick Ratio of 1.11 indicates that XRAY should not have too much problems paying its short term obligations.
XRAY's Quick ratio of 1.11 is on the low side compared to the rest of the industry. XRAY is outperformed by 71.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
The earnings per share for XRAY have decreased by -7.07% in the last year.
Measured over the past years, XRAY shows a decrease in Earnings Per Share. The EPS has been decreasing by -7.38% on average per year.
The Revenue has decreased by -5.78% in the past year.
XRAY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.17% yearly.
EPS 1Y (TTM)-7.07%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%6.12%
Revenue 1Y (TTM)-5.78%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.88%
3.2 Future
The Earnings Per Share is expected to grow by 11.25% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.02% on average over the next years.
EPS Next Y15.36%
EPS Next 2Y11.33%
EPS Next 3Y10.55%
EPS Next 5Y11.25%
Revenue Next Year-4.02%
Revenue Next 2Y-0.94%
Revenue Next 3Y0.27%
Revenue Next 5Y2.02%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.70, which indicates a rather cheap valuation of XRAY.
XRAY's Price/Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 96.34% of the companies in the same industry.
XRAY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.38.
XRAY is valuated cheaply with a Price/Forward Earnings ratio of 6.36.
XRAY's Price/Forward Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 98.43% of the companies in the same industry.
XRAY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.7 | ||
| Fwd PE | 6.36 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 96.34% of the companies listed in the same industry.
86.91% of the companies in the same industry are more expensive than XRAY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.02 | ||
| EV/EBITDA | 7.37 |
4.3 Compensation for Growth
XRAY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.5
PEG (5Y)N/A
EPS Next 2Y11.33%
EPS Next 3Y10.55%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.48%, XRAY is a good candidate for dividend investing.
XRAY's Dividend Yield is rather good when compared to the industry average which is at 1.73. XRAY pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.38, XRAY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.48% |
5.2 History
On average, the dividend of XRAY grows each year by 11.21%, which is quite nice.
XRAY has paid a dividend for at least 10 years, which is a reliable track record.
XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
The earnings of XRAY are negative and hence is the payout ratio. XRAY will probably not be able to sustain this dividend level.
The dividend of XRAY is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP-13.49%
EPS Next 2Y11.33%
EPS Next 3Y10.55%
13.16
-0.26 (-1.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners105.53%
Inst Owner Change-6.76%
Ins Owners0.33%
Ins Owner Change3.42%
Market Cap2.63B
Analysts70.43
Price Target17.13 (30.17%)
Short Float %3.85%
Short Ratio2.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.48% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-13.49%
Div Incr Years6
Div Non Decr Years30
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.27%
Min EPS beat(2)1.17%
Max EPS beat(2)45.37%
EPS beat(4)3
Avg EPS beat(4)2.65%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)0.57%
EPS beat(12)6
Avg EPS beat(12)3.68%
EPS beat(16)8
Avg EPS beat(16)3.31%
Revenue beat(2)1
Avg Revenue beat(2)-0.45%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.89%
Revenue beat(12)5
Avg Revenue beat(12)-1.6%
Revenue beat(16)5
Avg Revenue beat(16)-1.99%
PT rev (1m)-7.14%
PT rev (3m)-6.93%
EPS NQ rev (1m)-0.79%
EPS NQ rev (3m)-2.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.7 | ||
| Fwd PE | 6.36 | ||
| P/S | 0.72 | ||
| P/FCF | 19.02 | ||
| P/OCF | 9.28 | ||
| P/B | 1.34 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.37 |
EPS(TTM)1.71
EY12.99%
EPS(NY)2.07
Fwd EY15.73%
FCF(TTM)0.69
FCFY5.26%
OCF(TTM)1.42
OCFY10.78%
SpS18.4
BVpS9.83
TBVpS-3.51
PEG (NY)0.5
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.64% | ||
| ROE | -48.42% | ||
| ROCE | 5.89% | ||
| ROIC | 4.66% | ||
| ROICexc | 5.02% | ||
| ROICexgc | 12.12% | ||
| OM | 7.87% | ||
| PM (TTM) | N/A | ||
| GM | 51.92% | ||
| FCFM | 3.76% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexcg growth 3Y-31.16%
ROICexcg growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score5
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.13 | ||
| Debt/FCF | 17.41 | ||
| Debt/EBITDA | 3.5 | ||
| Cap/Depr | 42.15% | ||
| Cap/Sales | 3.95% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 44.71% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 1.09 |
F-Score5
WACC6.36%
ROIC/WACC0.73
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.07%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%6.12%
EPS Next Y15.36%
EPS Next 2Y11.33%
EPS Next 3Y10.55%
EPS Next 5Y11.25%
Revenue 1Y (TTM)-5.78%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.88%
Revenue Next Year-4.02%
Revenue Next 2Y-0.94%
Revenue Next 3Y0.27%
Revenue Next 5Y2.02%
EBIT growth 1Y5.86%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year50.11%
EBIT Next 3Y18.87%
EBIT Next 5Y12.9%
FCF growth 1Y-30.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-15.27%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%